Our team

Meet our dedicated team of scientists and researchers

Neobe's leadership has decades of combined experience in cancer biology, advanced therapies and bacterial engineering, supported by recognized leaders in oncology business development. Our world class R&D team is committed to a culture of collaboration and inclusion, working together to bring our engineered LBPs to the clinic.

Co-founders

2people

Pedro Correa de Sampaio, Ph.D.
Co-founder and CEO
Tumour microenvironment expert with over 12 years of research experience in top institutions including CRUK Cambridge Institute and MD Anderson Cancer Center. Authored multiple publications in immunooncology and contributed to development of innovative IO cell therapies at Triumvira Immunologics.
Annelise Soulier, Ph.D.
Co-founder and CSO
Expert in molecular biology, microbiology and bacterial engineering. Formerly at Prokarium, with over 7 years experience in the engineering and development of bacterial therapeutic products for different disease indications. Co-inventor of patented engineered live biotherapeutics currently in clinical trials.

Board of directors

4people

Keith Blundy, Ph.D.
Director and Chairperson
Former CEO of Cancer Research Technology and STORM Therapeutics, with experience in licensing, drug development and venture fundraising. Previously a director of KuDOS Pharmaceuticals, Mission Therapeutics and Inivata.
Julie Wolf, Ph.D.
Investor Director · 2048 Ventures
Leads biotech and healthcare at 2048 Ventures, with investments in over 50 startups. Previously Chief Scientific Officer and a founding member of the investment team at SOSV's IndieBio New York.
Imelda Juniarsih, Ph.D.
Investor Director · Pioneer Group
Investment Associate Director at Pioneer Group, covering life sciences, biotech and MedTech. Advises early-stage healthcare startups on IP, commercialisation and investment strategy. PhD in Biotechnology, University of Manchester.
Torquil Jackson, Ph.D.
Board Observer · Cancer Research Horizons
Investment Manager on Cancer Research Horizons' Ventures team, evaluating oncology investments and helping Cancer Research UK investigators build start-ups. BSc in pharmacology and PhD in neurobiology.